Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia

被引:23
|
作者
Witjes, WPJ
Rosier, PFWM
deWildt, MJAM
vanIersel, MP
Debruyne, FMJ
delaRosette, JJMCH
机构
[1] Department of Urology, University Hospital Nijmegen, Nijmegen
来源
JOURNAL OF UROLOGY | 1996年 / 155卷 / 04期
关键词
prostate; prostatic hyperplasia; urodynamics; adrenergic alpha receptor blockaders;
D O I
10.1016/S0022-5347(01)66255-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We evaluated the urodynamic and clinical effects of terazosin in patients with symptomatic benign prostatic hyperplasia (BPH). Materials and Methods: A total of 45 patients who participated in a multicenter trial was evaluated with urodynamic pressure-flow studies before and after 26 weeks of treatment. Results: Maximum flow rate and symptom score improved significantly in 22 patients with and 11 without bladder outlet obstruction who completed 26 weeks of treatment. In patients with bladder outlet obstruction the condition was significantly reduced and in patients without obstruction, significant urodynamic changes could not be detected. Conclusions: Terazosin treatment results in symptomatic relief and improved urinary flow in patients with and without bladder outlet obstruction, and in significant improvement in patients with urodynamically proved obstruction.
引用
下载
收藏
页码:1317 / 1323
页数:7
相关论文
共 50 条
  • [1] Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia
    Tanaka, Y
    Masumori, N
    Itoh, N
    Sato, Y
    Takahashi, A
    Ogura, H
    Furuya, S
    Tsukamoto, T
    JOURNAL OF UROLOGY, 2002, 167 (06): : 2492 - 2495
  • [2] Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia
    Akbay, E
    Bozlu, M
    Doruk, E
    Akbay, E
    Çayan, S
    Ulusoy, E
    UROLOGIA INTERNATIONALIS, 2001, 67 (02) : 156 - 159
  • [3] A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients
    Okada, H
    Kamidono, S
    Yoshioka, T
    Okuyama, A
    Ozono, S
    Hirao, Y
    Okajima, E
    Yamamoto, K
    Kishimoto, T
    Park, Y
    Kurita, T
    BJU INTERNATIONAL, 2000, 85 (06) : 676 - 681
  • [4] EFFICACY OF TERAZOSIN IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
    MATZKIN, H
    SOLOWAY, MS
    RANGEL, MC
    LADDU, A
    EUROPEAN UROLOGY, 1992, 21 (02) : 126 - 130
  • [5] SAFETY ASSESSMENT OF TERAZOSIN IN THE TREATMENT OF PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA - A COMBINED ANALYSIS
    LOWE, FC
    UROLOGY, 1994, 44 (01) : 46 - 51
  • [7] CLINICAL-EXPERIENCES WITH TERAZOSIN IN BENIGN PROSTATIC HYPERPLASIA
    FABRICIUS, PG
    PERFUSION, 1993, 6 (11): : 456 - 456
  • [8] Side effects of terazosin in the treatment of benign prostatic hyperplasia
    McKiernan, JM
    Lowe, FC
    SOUTHERN MEDICAL JOURNAL, 1997, 90 (05) : 509 - 513
  • [9] THE SAFETY, EFFICACY AND COMPLIANCE OF TERAZOSIN THERAPY FOR BENIGN PROSTATIC HYPERPLASIA
    LEPOR, H
    MERETYK, S
    KNAPPMALONEY, G
    JOURNAL OF UROLOGY, 1992, 147 (06): : 1554 - 1557
  • [10] Effect of terazosin on clinical benign prostatic hyperplasia in older adults
    Mudiyala, R
    Ahmed, A
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (03) : 424 - 426